Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), taking place May 12-16, 2026 in Padua, Italy. The meeting, hosted by the University of Padova, will focus on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint is making clinical progress with its VMS+™ product family.
Founded in 1963, AEPC is the world’s largest association in congenital cardiology, bringing together over 1,000 specialists from 32 European countries and beyond. Ventripoint will exhibit alongside its European distributor, AngioPro, engaging with clinicians from the global congenital cardiology community. A key focus will be on using VMS+™ to track cardiac function over time in congenital heart disease (CHD) patients. This approach aligns with the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and affirm echocardiography as the key modality for longitudinal assessment of ventricular function (Baumgartner et al., European Heart Journal, 2021).
Ventripoint’s priority for 2026 is accelerating integration of VMS+™ into routine clinical practice. The latest release, VMS+™ 4.0, streamlines workflows, reduces assessment time, and makes advanced cardiac analysis accessible at the point of care. At a patient’s first echocardiogram, VMS+™ provides volumetric cardiac measurements equivalent to MRI, supporting clinical decision-making across a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
The company’s flagship VMS+™ product family, powered by proprietary KBR technology, delivers volumetric cardiac measurements with accuracy equivalent to MRI. It is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada. As congenital heart disease patients require lifelong monitoring, Ventripoint’s technology offers a cost-effective alternative to MRI, potentially improving outcomes and reducing healthcare costs. The AEPC meeting provides a platform to demonstrate how VMS+™ can enhance care pathways for CHD patients across Europe and beyond.
